Article Information
History
- January 12, 2023.
Article Versions
- Version 1 (July 17, 2022 - 08:48).
- Version 2 (September 23, 2022 - 08:07).
- You are viewing Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Hiroshi Yotsuyanagi, MD, PhDa,
- Norio Ohmagari, MD, PhDb,
- Yohei Doi, MD, PhDc,d,
- Takumi Imamura, MSe,
- Takuhiro Sonoyama, MD, PhDe,
- Genki Ichihashi, MPharme,
- Takao Sanaki, PhDf,
- Yuko Tsuge, MSe,
- Takeki Uehara, PhDe,* and
- Hiroshi Mukae, MD, PhDg
- aThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- bDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
- cDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- dDepartments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
- eDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- fResearch Division, Shionogi & Co., Ltd., Osaka, Japan
- gDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
- ↵*Corresponding author Takeki Uehara, Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Address: 8F, Nissay Yodoyabashi East, 3-3-13 Imabashi, Chuo-ku, Osaka 541-0042, Japan, Email: takeki.uehara{at}shionogi.co.jp, Telephone: +81-6-6209-6907
Posted January 12, 2023.
A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
